用于治疗三阴性乳腺癌的PI3K/AKT/mTOR抑制剂 - Suppr

PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.

作者信息

Altundag Kadri

机构信息

MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey.

出版信息

Med Oncol. 2024 Oct 14;41(11):279. doi: 10.1007/s12032-024-02515-1.

DOI:10.1007/s12032-024-02515-1

PMID:39400749

Abstract

摘要

相似文献

PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.

Med Oncol. 2024 Oct 14;41(11):279. doi: 10.1007/s12032-024-02515-1.

PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.

Cancer Treat Rev. 2025 Jan;132:102861. doi: 10.1016/j.ctrv.2024.102861. Epub 2024 Nov 19.

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.

Breast Cancer. 2024 Jul;31(4):539-551. doi: 10.1007/s12282-024-01567-5. Epub 2024 Apr 17.

Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.

Mini Rev Med Chem. 2024;24(16):1496-1520. doi: 10.2174/0113895575270904231129062137.

A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy.

Curr Med Chem. 2025;32(10):1865-1873. doi: 10.2174/0109298673327425240815065221.

Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy.

Biochem Pharmacol. 2025 Jun;236:116850. doi: 10.1016/j.bcp.2025.116850. Epub 2025 Mar 4.

Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.

Eur J Cancer. 2024 Aug;207:114145. doi: 10.1016/j.ejca.2024.114145. Epub 2024 Jun 8.

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.

J Hematol Oncol. 2020 Feb 22;13(1):13. doi: 10.1186/s13045-020-0846-y.

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.

Semin Cancer Biol. 2019 Dec;59:125-132. doi: 10.1016/j.semcancer.2019.07.009. Epub 2019 Jul 16.

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway.

Mol Oncol. 2025 Jan;19(1):225-247. doi: 10.1002/1878-0261.13703. Epub 2024 Aug 2.

引用本文的文献

Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer.

World J Clin Oncol. 2025 May 24;16(5):104623. doi: 10.5306/wjco.v16.i5.104623.

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Front Oncol. 2025 Jan 9;14:1515387. doi: 10.3389/fonc.2024.1515387. eCollection 2024.

本文引用的文献

The treatment landscape of triple-negative breast cancer.

Med Oncol. 2024 Aug 29;41(10):236. doi: 10.1007/s12032-024-02456-9.

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.

Breast Cancer. 2024 Jul;31(4):539-551. doi: 10.1007/s12282-024-01567-5. Epub 2024 Apr 17.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献